COmBining memantine And cholinesterase inhibitors in Lewy body dementia Treatment trial (COBALT)
The Memory & Cognition Research Delivery Team at Oxford Health NHS Foundation Trust are looking for participants for a medical research trial.
The trial will look at the use of a drug called Memantine for treatment of people with Dementia with Lewy Bodies (DLB) and Parkinson’s Disease Dementia (PDD) symptoms.
The aim of the COBALT trial is to find out if Memantine treatment can help improve overall health and functioning for people with DLB or PDD.
Potential participants should be currently taking cholinesterase inhibitors (for example, Donepezil also called Aricept’).
If you agree to take part, you will join one of two treatment groups for 12 months:
• a placebo (‘dummy’ drug) group
OR
• a medication (Memantine) group
You will have planned visits and phone calls with the local trial team, who will ask you about your symptoms, how you feel and your trial treatment.
A family member or person who knows you well will also be asked to answer questions about your symptoms and about how they are feeling.
Please contact the trial team direct for more information on 01865 902694.
You can also email the trial team on: dementia.reserach@oxfordhealth.nhs.uk